SOURCE: Leerink Swann & Company

June 10, 2005 09:39 ET

Leerink Swann & Company Initiates Coverage of Illumina, Inc. (NASDAQ: ILMN)

BOSTON, MA -- (MARKET WIRE) -- June 10, 2005 -- This morning, Senior Biotechnology and Life Sciences Analyst John L. Sullivan initiated coverage of Illumina, Inc. with an Outperform rating. Mr. Sullivan bases his investment thesis on his belief that the competitive landscape in the genotyping products market has yet to be set, and market share is available for additive new technologies like Illumina's.

About Illumina, Inc.

Illumina, Inc. (NASDAQ: ILMN) develops tools for the large-scale analysis of genetic variation and function, the results of which will pave the way for personalized medicine. The company's technology platform also extends to other applications such as high-throughput screening of pharmaceutical compounds and chemical detection. Illumina, Inc. is headquartered in San Diego, CA.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564